References
- Immerman SC, Sener SF, Khandekar JD. Causes and evaluation of tumor-induced hypoglycemia. Arch Surg 1982; 117 (7): 905–8.
- Gorden P, Comi RJ, Maton PN, Go VL. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 1989; 110: 35–50.
- Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 1995: 80 (11): 3267–72.
- Priou A, Levesque G, Simonetta C, Lancranjan I, Roger P, Jaquet P. Long acting sandostatin (sandostatin LAR) in the treatment of acromegaly. Ann Endocrinol (Paris) 1995; 56 (3): 213–8.
- Lunetta M, De Mauro M, Le Moli R, Nicoletti F. Effects of octreotide on glycaemic control disposal, hepatic glucose production and counterregulatory hormones secretion in type 1 and type 2 insulin treated diabetic patients. Diabetes Res Clin Pract 1997; 38: 81–89.
- Brunner JE, Kruger DF, Basha MA, Meiri E, Kaatz SS. Hypoglycemia in acromegalic patients treated with long acting somatostatin analogue (SMS 201-995). Horm Metab Res 1989; 21 (5): 282–284.
- Gama R, Marks V, Wright J, Teale JD. Octreotide exacerbated fasting hypoglycemia in a patient with a proinsulino-ma; the glucostatic importance of pancreatic glucagon. Clin Endocrinol (Oxf) 1995; 43 (1): 117–120.
- Krejs G. Physiological role of somatostatin in the diges-tive tract: gastric acid secretion, intestinal absorption, and motility. Scand J Gastroenterol Suppl 1986; 119: 47–53.
- Gerich JE. Hypoglycemia. In: Endocrinology. DeGroot LJ, Jameson JL. 4th edition. W.B. Saunders Company, Philadelphia, 2001, Volume 1: 929-930.
- Gagel RF. Endocrine manifestations of tumors: Ectopic hormone production. In: Cecil Textbook of Medicine. Goldman L, Bennett JC. 21 edition. W.B. Saunders Company, Philadelphia, 2000: 1050.
- Ron D, Powers AC, Pandian MR, Godine JE, Axelrod L. Increased insulin-like growth factor II production and cose-went seppression of growth hormone secretion: a dual mech-anism for tumor-induced hypoglycemia. J Clin EndocrinolMetab 1989; 68: 701–6.
- Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless R. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31 (11): 1133–40.
- Lamberts S, Uitterlinden G, Verschoor P, van Dongen L, del Pozo E. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 1985; 313 (25): 1576–80.
- Daughaday WH. Hypoglycemia in patients with non-islet cell tumors. Endocrinol Metab Clin North Am 1989; 18 (1): 91–101.
- Baxter RC, Holman SR, Corbould A, Stranks S, Ho PJ, Braund W. Regulation of the insulin-like growth factors and their binding proteins by glucocorticoid and growth hor-mone in nonislet cell tumor hypoglycemia. J Clin Endocrinol Metab 1995; 80 (9): 2700–8.